SG11202105112RA - Radioimmunoconjugates and checkpoint inhibitor combination therapy - Google Patents

Radioimmunoconjugates and checkpoint inhibitor combination therapy

Info

Publication number
SG11202105112RA
SG11202105112RA SG11202105112RA SG11202105112RA SG11202105112RA SG 11202105112R A SG11202105112R A SG 11202105112RA SG 11202105112R A SG11202105112R A SG 11202105112RA SG 11202105112R A SG11202105112R A SG 11202105112RA SG 11202105112R A SG11202105112R A SG 11202105112RA
Authority
SG
Singapore
Prior art keywords
radioimmunoconjugates
combination therapy
checkpoint inhibitor
inhibitor combination
checkpoint
Prior art date
Application number
SG11202105112RA
Inventor
Julie Metcalf
Natalie Grinshtein
Meiduo Hu
John Valliant
Eric Burak
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of SG11202105112RA publication Critical patent/SG11202105112RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1036—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11202105112RA 2018-12-03 2019-12-03 Radioimmunoconjugates and checkpoint inhibitor combination therapy SG11202105112RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862774847P 2018-12-03 2018-12-03
PCT/IB2019/001342 WO2020115556A1 (en) 2018-12-03 2019-12-03 Radioimmunoconjugates and checkpoint inhibitor combination therapy

Publications (1)

Publication Number Publication Date
SG11202105112RA true SG11202105112RA (en) 2021-06-29

Family

ID=70973593

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202105192WA SG11202105192WA (en) 2018-12-03 2019-12-03 Radioimmunoconjugates and dna damage and repair inhibitor combination therapy
SG11202105112RA SG11202105112RA (en) 2018-12-03 2019-12-03 Radioimmunoconjugates and checkpoint inhibitor combination therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202105192WA SG11202105192WA (en) 2018-12-03 2019-12-03 Radioimmunoconjugates and dna damage and repair inhibitor combination therapy

Country Status (18)

Country Link
US (5) US20220088231A1 (en)
EP (2) EP3890790A4 (en)
JP (2) JP2022513700A (en)
KR (2) KR20210099074A (en)
CN (3) CN113164632A (en)
AU (2) AU2019393257A1 (en)
BR (2) BR112021010799A2 (en)
CA (2) CA3119917A1 (en)
CL (2) CL2021001433A1 (en)
EA (2) EA202191556A1 (en)
IL (2) IL283613A (en)
MA (2) MA54401A (en)
MX (2) MX2021006408A (en)
PE (2) PE20211286A1 (en)
PH (2) PH12021551237A1 (en)
SG (2) SG11202105192WA (en)
WO (2) WO2020115556A1 (en)
ZA (1) ZA202103429B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516170A (en) * 2019-01-04 2022-02-24 アクティニウム ファーマシューティカルズ インコーポレイテッド Methods for treating cancer using a combination of PARP inhibitors and antibody radioactive material conjugates
EP4087588A1 (en) * 2020-01-10 2022-11-16 Fusion Pharmaceuticals Inc. Sustained immunotherapy
WO2021207086A1 (en) * 2020-04-06 2021-10-14 Fusion Pharmaceuticals Inc. Tem-1-targeted radioimmunoconjugates and uses thereof
WO2022169634A1 (en) * 2021-02-02 2022-08-11 Unm Rainforest Innovations Combination therapy for the treatment of cancer
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
CA3233733A1 (en) * 2021-09-29 2023-04-06 National Research Council Of Canada Egfrviii-targeted compounds and uses thereof
TW202325344A (en) * 2021-11-02 2023-07-01 加拿大商融合製藥公司 Methods of treating cancer
WO2023141717A1 (en) * 2022-01-28 2023-08-03 Fusion Pharmaceuticals Inc. Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5053503A (en) * 1989-02-17 1991-10-01 Centocor Chelating agents
JPH07503124A (en) 1991-06-14 1995-04-06 ゾーマ・コーポレーション Antibody fragments and their complexes produced by microorganisms
JP3876002B2 (en) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト Novel methods for producing anti-human antigen receptors and their use
US7736651B1 (en) * 2000-11-24 2010-06-15 Sloan-Kettering Institute For Cancer Research Alpha emitting constructs and uses thereof
JP2008526234A (en) * 2005-01-05 2008-07-24 バイオジェン・アイデック・エムエイ・インコーポレイテッド CRIPTO binding molecule
MX2008012146A (en) * 2006-03-28 2008-10-03 Biogen Idec Inc Anti-igf-ir antibodies and uses thereof.
WO2011060233A1 (en) * 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
DK3134127T3 (en) * 2014-04-25 2020-03-16 Rinat Neuroscience Corp Antibody drug conjugates with high drug loading
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
WO2016162356A1 (en) * 2015-04-07 2016-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-pd-l1 immunotoxin for use in therapy
EP3286213B1 (en) * 2015-04-20 2021-08-04 Etubics Corporation Methods and compositions for combination immunotherapy
EP3285809B1 (en) * 2015-04-20 2019-09-11 eFFECTOR Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
WO2016196377A1 (en) * 2015-05-29 2016-12-08 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
MY194127A (en) * 2016-01-11 2022-11-14 Univ Leland Stanford Junior Chimeric proteins and methods of immunotherapy
EP3202788A1 (en) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialin-binding antibody
TWI786044B (en) * 2016-05-13 2022-12-11 美商再生元醫藥公司 Methods of treating skin cancer by administering a pd-1 inhibitor
US11633506B2 (en) * 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
WO2018031507A1 (en) 2016-08-09 2018-02-15 Angimmune, Llc Treatment of cancer using a combination of immunomodulation and check point inhibitors
US11655304B2 (en) * 2016-09-16 2023-05-23 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
KR20190095280A (en) * 2016-12-12 2019-08-14 다이이찌 산쿄 가부시키가이샤 Combination of Antibody-Drug Conjugates and Immune Checkpoint Inhibitors
WO2018153975A1 (en) * 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
US11433148B2 (en) * 2017-05-05 2022-09-06 Centre For Probe Development And Commercialization IGF-1R monoclonal antibodies and uses thereof
KR20200044968A (en) * 2017-09-13 2020-04-29 라디뮨 테라퓨틱스 인코포레이티드 Melanin antibodies and uses thereof
WO2019101789A1 (en) * 2017-11-22 2019-05-31 Nordic Nanovector Asa Radioimmunoconjugates in combination with other drugs as treatment against nhl
CA3130747A1 (en) * 2019-02-21 2020-08-27 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates

Also Published As

Publication number Publication date
BR112021010799A2 (en) 2021-08-24
AU2019393257A1 (en) 2021-06-03
WO2020115548A1 (en) 2020-06-11
BR112021010670A2 (en) 2021-08-24
CN117482261A (en) 2024-02-02
EP3890789A1 (en) 2021-10-13
US20210290789A1 (en) 2021-09-23
MX2021006407A (en) 2021-10-22
EA202191556A1 (en) 2021-10-14
JP2022513700A (en) 2022-02-09
CN113164632A (en) 2021-07-23
EP3890790A1 (en) 2021-10-13
US11446401B2 (en) 2022-09-20
CL2021001433A1 (en) 2021-12-03
KR20210099073A (en) 2021-08-11
CA3119917A1 (en) 2020-06-11
PE20211961A1 (en) 2021-10-04
EP3890789A4 (en) 2022-12-14
CA3119915A1 (en) 2020-06-11
JP2022511471A (en) 2022-01-31
IL283613A (en) 2021-07-29
EP3890790A4 (en) 2022-12-14
ZA202103429B (en) 2023-11-29
US20210290788A1 (en) 2021-09-23
IL283598A (en) 2021-07-29
MA54401A (en) 2021-10-13
CL2021001432A1 (en) 2021-12-17
EA202191557A1 (en) 2021-10-14
KR20210099074A (en) 2021-08-11
MX2021006408A (en) 2021-10-22
US20220088230A1 (en) 2022-03-24
US20230270895A1 (en) 2023-08-31
PE20211286A1 (en) 2021-07-19
AU2019394888A1 (en) 2021-06-10
WO2020115556A1 (en) 2020-06-11
MA54399A (en) 2021-10-13
CN113474014A (en) 2021-10-01
SG11202105192WA (en) 2021-06-29
PH12021551282A1 (en) 2021-12-06
PH12021551237A1 (en) 2021-11-03
US20220088231A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
IL283598A (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
IL265274A (en) Antibody and checkpoint inhibitor combination therapy
GB201820166D0 (en) Therapeutic agents
GB201820165D0 (en) Therapeutic agents
IL258500A (en) Combination therapy with glutaminase inhibitors and immuno-oncology agents
EP3572400C0 (en) Ezh2 inhibitor and use thereof
IL260222A (en) Bromodomain and extra-terminal protein inhibitor combination therapy
IL282350A (en) Rgmc-selective inhibitors and use thereof
IL276609A (en) Combination therapy with apilimod and glutamatergic agents
GB201805816D0 (en) Therapeutic agents
LT3532059T (en) Bromodomain and extra-terminal protein inhibitor combination therapy
EP3370773A4 (en) Combination therapy of immunotoxin and checkpoint inhibitor
IL286079A (en) Imidazolonylquinoline compounds and therapeutic uses thereof
GB201715194D0 (en) Compounds and their therapeutic use
IL309243A (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
IL283687A (en) Usp19 inhibitors for use in therapy
GB201918541D0 (en) Therapeutic compounds and their use
IL282157A (en) Compounds and therapeutic uses thereof
IL279000A (en) Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors
GB201905520D0 (en) Compounds and their therapeutic use
GB201813312D0 (en) Compounds and their therapeutic use
GB201908884D0 (en) Inhibitors and use
GB201820164D0 (en) Therapeutic agents
GB201820168D0 (en) Therapeutic agents
GB201820172D0 (en) Therapeutic agents